Ligand validation:2FG6

SN0: N-(3-CARBOXYPROPANOYL)-L-NORVALINE

SN0 is a Ligand Of Interest in 2FG6 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2FG6_SN0_Z_349	81%	39%	0.119	0.97	0.94	1.41	-	1	0	0	100%	1
2FG6_SN0_Y_347	75%	47%	0.13	0.965	0.77	1.25	-	3	1	0	100%	1
2FG6_SN0_E_355	61%	56%	0.153	0.943	0.75	0.96	-	-	2	0	100%	1
2FG6_SN0_C_351	60%	49%	0.162	0.949	0.77	1.2	-	2	2	0	100%	1
2FG6_SN0_X_345	54%	47%	0.182	0.946	0.73	1.29	-	2	0	0	100%	1
2FG6_SN0_D_353	45%	46%	0.197	0.93	0.87	1.2	-	2	1	0	100%	1
2FG7_SN0_Z_349	70%	48%	0.154	0.971	0.75	1.26	-	3	1	0	100%	1
3L04_SN0_A_345	89%	51%	0.096	0.976	0.83	1.06	-	1	0	0	100%	1
3L06_SN0_A_345	63%	51%	0.162	0.958	0.77	1.12	-	2	0	0	100%	1
3L05_SN0_A_345	40%	47%	0.219	0.933	0.79	1.26	-	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.